Business Wire

Egle Therapeutics Strengthens its Leadership Team with the Appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer

Share

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Monica Gostissa, PhD, as Chief Scientific Officer and Reno Winter, PhD, as Chief Technical Officer.

“I am delighted to welcome Monica and Reno. They both bring an outstanding leadership to progress Egle towards a rich proprietary pipeline and the development of our therapeutic assets,” said Vincent Brichard, MD, PhD, Egle’s Interim CEO and Board member.

“I'm excited to join Egle Therapeutics to help develop novel immunotherapies targeting T regulatory cells for oncology and autoimmune diseases. I have been deeply impressed by the commitment of Egle’s staff, scientists, management, Board of Directors and Investors to advancing its groundbreaking science. With all developments accomplished so far, and together with the talented people we have, I am confident that we will deliver highly successful and much needed therapeutic options for patients in the years ahead,” said Monica Gostissa, CSO at Egle Therapeutics. As CSO, Dr. Gostissa will be responsible for all research, early development and translational activities.

“I am happy to be part of Egle Therapeutics’ leadership team to contribute my expertise in CMC and beyond to the company’s mission. I am truly enthusiastic about turning bold ideas into life-changing treatments, to innovate, and support creating new therapies. Excited for the journey ahead, I am ready to collaborate with a team that shares a common vision of making a significant impact on patients’ lives,” said Reno Winter, CTO at Egle Therapeutics. As CTO, Dr. Winter will be responsible for all manufacturing activities.

Dr. Gostissa has led preclinical programs at small and large biotech companies, focusing on how to best translate scientific insights into innovative cancer therapeutics. Most recently, she was Vice President of Preclinical Sciences at Jounce Therapeutics, where she contributed to establish the company’s scientific strategy and to oversee a broad preclinical portfolio of immuno-modulatory antibodies.

During her time at Jounce, Dr. Gostissa led efforts that enabled two IND applications, was involved in a successful outlicensing deal, and established and grew effective multi-disciplinary teams. Before starting her career in biotech, Dr. Gostissa spent many years in academic research, where she acquired a deep knowledge in cell biology, oncology and tumor immunology. Dr. Gostissa obtained her PhD in molecular genetics from the International School for Advanced Studies in Trieste, Italy, and completed post-doctoral studies at Boston Children's Hospital/Harvard Medical School. She co‑authored over 40 peer-reviewed publications and was the recipient of several awards, including a Leukemia and Lymphoma Society Special Fellow Award and a V Foundation Scholar Award.

Dr. Winter provides more than 10 years of experience in operationally leading and managing analytical & process development and external manufacturing activities. His expertise ranges from cell bank generation to drug substance and drug product manufacturing and supply.

Dr. Winter joined Egle Therapeutics in 2023, and assumes responsibility for the design, the establishment, and management of the manufacturing and supply strategy, as well as for the implementation of internal requirements and procedures to comply with applicable quality-related regulations and guidelines.

Previously, Dr. Winter worked as Head of CMC for a clinical-stage biotech company in Germany and as CMC Lead for Baxter/Shire PLC in Austria on numerous Investigational New Drug programs. In his past roles, he headed different teams to deliver and master all clinical trial-enabling CMC activities and actively contributed to numerous clinical trial applications and patents.

Dr. Winter is a trained biochemist and received his PhD in Natural Sciences from the Martin Luther University Halle-Wittenberg, Germany.

About Egle Therapeutics SAS (Egle)

Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle ambition to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently developed in IND-enabling studies.

Find out more at www.egle-tx.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

contact@egle-tx.com / 0033 (0)1 86 64 08 57

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Binarly Launches Next-Generation Transparency Platform to Elevate Software Supply Chain Security23.4.2024 18:00:00 CEST | Press release

Binarly, provider of an industry leading AI-powered firmware and software supply chain security platform, announces the release of the Binarly Transparency Platform v2.0 with features for continuous post-build compliance, visibility into the security posture of IoT and XIoT devices, and the ability to identify malicious behavior and hidden backdoors within binaries based on their behavior. Learn more here. Based on the company’s proprietary Binary Risk Intelligence technology, the new innovations underscore Binarly's commitment to pioneering solutions that enhance transparency and security across firmware and software ecosystems. Founded in 2021 with a vision to increase transparency in the software supply chain through advanced program analysis, Binarly’s flagship platform has automated the discovery of hundreds of new vulnerabilities, preemptively addressing our customers' security risks before they could escalate. Binarly’s patented approach, powered by modern AI, has proactively ne

Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 2723.4.2024 17:54:00 CEST | Press release

On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/ Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire) Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration

DataXstream Expands into Nordic Region with Successful Go Live for Martin & Servera23.4.2024 15:07:00 CEST | Press release

DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry. Learn more about DataXstream OMS+ here. Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization. Working with DataXstream’s LATAM delivery team, Kötthalle

Autel Energy’s Global ESG Launch Is A Success: Around 5,000 Trees Planted In EVergreen's Inaugural Tree Planting Initiative23.4.2024 15:00:00 CEST | Press release

Autel Energy, a leading provider of electric vehicle (EV) charging solutions and services, proudly announces the successful conclusion of its first EVergreen Global Tree Planting Initiative, which saw hundreds of participants around the globe plant an estimated 5,000 trees in the initial phase. This activity offsets an estimated 2,190,000 kilograms of carbon emissions (CO2), and emphasizes Autel Energy's and partners' commitment to their ESG goals towards a sustainable tomorrow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423142946/en/ Autel Energy’s Global ESG Launch A Success (Graphic: Business Wire) Partner Experience and NGO Feedback Reflecting on the Initiative, one partner remarked, “We show the world we are not only talking about a better world and clean energy, but we are really taking steps by putting shovels in the ground.” The non-governmental organizations (NGO) involved expressed sincere gratitude for the

Ouro Partners with Bnext as Strategic Issuer for European Expansion Plans23.4.2024 14:00:00 CEST | Press release

Ouro, a global consumer financial services and technology innovator, and Bnext, a pioneering Spanish fintech, today announced a strategic partnership designating Bnext as Ouro’s strategic issuer in Europe for Ouro’s portfolio of consumer financial brands and products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423392141/en/ Roy Sosa, co-founder and CEO of Ouro (Photo: Business Wire) Ouro’s innovative payments portfolio includes its flagship Netspend brand that pioneered prepaid debit for underserved U.S. consumers looking for better access to payment products, and X World Wallet, its cashback-earning multicurrency wallet and payments app for international travelers and digital nomads looking for more convenience and value for their money. “The Bnext team has a proven track record of innovation and understanding of the customer needs of a growing European market for next generation payment products and services,” said

HiddenA line styled icon from Orion Icon Library.Eye